Citations

Mayo Clinic

Showing 10 of 108519 citations.

Control of Outflow Resistance by Soluble Adenylyl Cyclase
Lee, Yong Suk , Marmorstein, Alan D. , Marmorstein, Alan D

Journal of Ocular Pharmacology and Therapeutics | December 9, 2013 | Volume: 30 | Issue: 2-3 | Pages: 138-142

10.1089/jop.2013.0199 | PMID 24320087 Get It

Abstract Glaucoma is a leading cause of blindness in the United States affecting as many as 2.2 million Americans. All current glaucoma treatment strategies aim to reduce intraocular pressure, even in patients with normal tension glaucoma. Typically, this is accomplished by reducing the rate of aqueous flow by limiting aqueous production or enhancing drainage using drugs and surgery. Whereas these strategies are effective in diminishing vision loss, some patients continue to lose vision and many discontinue use of their medications because of undesirable side effects. Drugs known to be effective in altering conventional outflow have for the most part been abandoned from modern clinical practice due to undesirable side effects. Identification of new drugs that could enhance conventional outflow, would offer additional options in the treatment of glaucoma and ocular hypertension. To this end, our laboratory has recently uncovered a novel pathway for regulation of conventional outflow by the ciliary body. This pathway is dependent on soluble adenylyl cyclase, an enzyme that catalyzes the generation of cyclic adenosine 3′,5′ monophosphate (cAMP) in response to bicarbonate.
Transesophageal Echocardiographic Imaging of Ultrasound Lung Rockets
Rehfeldt, Kent H., Bruggink, Sean M., Pulido, Juan N.

Anesthesiology | December 9, 2013 | Volume: 121 | Issue: 6 | Pages: 1335-1335

10.1097/aln.0000000000000098 | PMID 25409196 Get It

Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma
Kaag, Matthew, Trost, Landon , Thompson, R. Houston, Favaretto, Ricardo L., Elliott, Vanessa, Maschino, Alexandra C., Vertosick, Emily , Dalbagni, Guido , Shariat, Shahrokh F. , Raman, Jay D. , Vertosick, Emily A

BJU International | December 9, 2013 | Volume: 114 | Issue: 5 | Pages: 674-679

10.1111/bju.12597 | PMID 24314050 Get It

Objectives To model renal function after radical nephroureterectomy ( RNU ) for upper tract urothelial carcinoma ( UTUC ). To identify predictors of renal function decline after surgery, thereby allowing the identification of patients likely to be ineligible for cisplatin‐based chemotherapy in the adjuvant setting. Patients and Methods We retrospectively identified 374 patients treated with RNU for UTUC at three centres between 1995 and 2010. Estimated glomerular filtration rate ( eGFR ) was calculated using Chronic Kidney Disease Epidemiology Collaboration equation before RNU and at early (1–5 months after RNU ) and late (>5 months) time points after RNU . Only patients deemed eligible for cisplatin‐based chemotherapy before RNU (preoperative glomerular filtration rate [ GFR ] ≥60 mL/min/1.73 m 2 ) were included. Multivariable analysis identified the preoperative predictors of eGFR after RNU at early postoperative and late postoperative time points. Results A total of 163 patients had an eligible early post‐ RNU eGFR measurement and 172 had an eligible late eGFR measurement. The median eGFR declined by 32% and did not show a significant trend toward recovery over time ( P = 0.4). On multivariable analysis preoperative eGFR and patient age were significantly associated with early and late postoperative eGFR , while C harlson comorbidity index score was significantly associated with late postoperative eGFR alone. Conclusions In patients with normal preoperative eGFR (≥60 mL/min/1.73 m 2 ), renal function decreases by one‐third after RNU and does not show evidence of recovery over time. Elderly patients and those with pre‐ RNU eGFR closer to 60 mL/min/1.73 m 2 (lower eGFR in the present cohort) are more likely to be ineligible for adjuvant cisplatin‐based chemotherapy regimens because of renal function loss after RNU .
Evaluating health‐related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume
Wijnands, Titus F. M., Neijenhuis, Myrte K., Kievit, Wietske , Nevens, Frederik , Hogan, Marie C. , Drenth, Joost P.H. , Torres, Vicente E. , Gevers, Tom J.G. , Hogan, Marie C , Drenth, Joost P H

Liver International | December 9, 2013 | Volume: 34 | Issue: 10 | Pages: 1578-1583

10.1111/liv.12430 | PMID 24313956 Get It

AbstractBackground & AimsPolycystic liver disease (PLD) follows a progressive course ultimately leading to severe hepatomegaly and mechanical complaints in a subset of patients. It is still unknown to what extent this compromises health‐related quality of life (HRQL). Our aim was to determine HRQL in PLD patients and investigate its association with concurrent abdominal symptoms and liver volume.MethodsPooled data of 92 severe PLD patients from two randomized clinical trials were used for our cross‐sectional analysis. HRQL was assessed using the generic short‐form health survey (SF‐36) resulting in eight scale scores and the summarizing physical (PCS) and mental component score (MCS). Subsequently, these were compared with the general population. Abdominal symptoms were measured with a standardized, 7‐point scale questionnaire in 54 patients. We dichotomized symptoms for absence or presence and compared them with the component scores. Finally, a possible correlation between liver volume and HRQL was explored.ResultsDemographics showed severe polycystic livers (mean 4906 ± 2315 ml). PCS was significantly lower compared with the general population (P < 0.001), in contrast with a similar MCS (P = 0.82). PLD patients had statistically significant (P < 0.05) diminished physical functioning, role physical, general health, vitality and social functioning scores. Upper‐ and lower abdominal pain and dyspnoea were significantly associated with a reduced PCS (P < 0.01). No correlation was found between liver volume and HRQL.ConclusionPolycystic liver disease patients had significantly lower HRQL in the physical dimension compared with the general population. Abdominal pain and dyspnoea had a significant impact on this physical dimension of HRQL.
Arthroscopic Femoral Neck Osteoplasty in the Treatment of Femoroacetabular Impingement
Chow, Roxanne M., Kuzma, Scott A., Krych, Aaron J. , Levy, Bruce A. , Krych, Aaron J

Arthroscopy Techniques | December 7, 2013 | Volume: 3 | Issue: 1 | Pages: No page available

10.1016/j.eats.2013.08.007 | PMID 24749017 Get It

Abstract Femoral neck osteoplasty is an integral component for successful treatment of femoroacetabular impingement. Current techniques allow this to be performed arthroscopically, and results are equivalent to those of open procedures when typical anterior and anterosuperior lesions are considered. The arthroscopic procedure is dependent on obtaining adequate visualization through capsular management and proper leg positioning, and it requires fluoroscopy to guide and verify an adequate resection. We present our preferred technique for arthroscopic femoral neck osteoplasty. Technique Video video See video under supplementary data.
Arthroscopic Capsular Repair in the Treatment of Femoroacetabular Impingement
Chow, Roxanne M., Engasser, William M. , Krych, Aaron J. , Levy, Bruce A. , Krych, Aaron J

Arthroscopy Techniques | December 7, 2013 | Volume: 3 | Issue: 1 | Pages: No page available

10.1016/j.eats.2013.08.006 | PMID 24749018 Get It

Abstract The role of capsular repair in the arthroscopic treatment of femoroacetabular impingement remains poorly defined. Some surgeons rarely repair the capsule, whereas others perform repairs routinely. There is little direct clinical evidence to guide surgeon decision making. When capsular repairs are performed, the procedure requires adequate visualization and careful suture placement either to re‐establish the patient's normal capsular volume or to plicate a redundant capsule in a hip with hyperlaxity preoperatively. We present our preferred technique for arthroscopic capsular repair. Technique Video video See video under supplementary data.
Quantitative Estimation of Insulin Sensitivity in Type 1 Diabetic Subjects Wearing a Sensor-Augmented Insulin Pump
Schiavon, Michele , Man, Chiara Dalla , Kudva, Yogish C. , Basu, Ananda , Cobelli, Claudio , Dalla Man, Chiara , Schiavon, Michele

Diabetes Care | December 7, 2013 | Volume: 37 | Issue: 5 | Pages: 1216-1223

10.2337/dc13-1120 | PMID 24319120 Get It

OBJECTIVE The goal was to develop a new index of insulin sensitivity in patients with type 1 diabetes estimated from continuous glucose monitoring (CGM) and subcutaneous insulin delivery data under carefully controlled conditions. RESEARCH DESIGN AND METHODS The database consists of 12 subjects with type 1 diabetes, studied during breakfast, lunch, and dinner, in a clinical research unit, wearing both subcutaneous insulin pump and CGM device. Frequent blood samples were drawn for measurements of plasma glucose and insulin concentrations in order to estimate insulin sensitivity with the oral minimal model (SIMM). The new index of insulin sensitivity (SISP) was calculated with a simple algebraic formula for each meal, using only CGM and insulin pump data and compared with SIMM. RESULTS SI SP was well correlated with SIMM (r = 0.825; P &lt; 10−8), and diurnal pattern was also similar to SIMM. CONCLUSIONS A novel method for estimating insulin sensitivity in subjects with type 1 diabetes on sensor-augmented insulin pump therapy has been presented. This new index correlates well with the reference oral minimal model estimate of insulin sensitivity. The knowledge of patient-specific insulin sensitivity and its diurnal variation can help in optimizing insulin therapy in type 1 diabetes and could also inform next-generation closed-loop control systems.
Refractory status epilepticus
Fountain, Nathan B. , Fugate, Jennifer E. , Fountain, Nathan

Neurology | December 7, 2013 | Volume: 82 | Issue: 8 | Pages: 650-651

10.1212/wnl.0000000000000008 | PMID 24319043 Get It

Cessation of contraction induces cardiomyocyte remodeling during zebrafish cardiogenesis
Yang, Jingchun , Hartjes, Katherine A., Nelson, Timothy J., Nelson, Timothy J. , Xu, Xiaolei

American Journal of Physiology-Heart and Circulatory Physiology | December 7, 2013 | Volume: 306 | Issue: 3 | Pages: H382-H395

10.1152/ajpheart.00721.2013 | PMID 24322613 Get It

Contraction regulates heart development via a complex mechanotransduction process controlled by various mechanical forces. Here, we exploit zebrafish embryos as an in vivo animal model to discern the contribution from different mechanical forces and identify the underlying mechanotransductive signaling pathways of cardiogenesis. We treated 2 days postfertilization zebrafish embryos with Blebbistatin, a myosin II inhibitor, to stop cardiac contraction, which induces a response termed cessation of contraction-induced cardiomyocyte (CM) enlargement (CCE). Accompanying the CCE, lateral fusion of myofibrils was attenuated within CMs. The CCE can be blunted by loss of blood in tail-docked zebrafish but not in cloche mutant fish, suggesting that transmural pressure rather than shear stress is accountable for the chamber enlargement. By screening a panel of small molecule inhibitors, our data suggested essential functions of phosphoinositide 3-kinase signaling and protein synthesis in CCE, which are independent of the sarcomere integrity. In summary, we defined a unique CCE response in genetically tractable zebrafish embryos. A panel of assays was established to verify the contribution from extrinsic forces and interrogate underlying signaling pathways.
The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
Hicks, Lisa K. , Bering, Harriet, Carson, Kenneth R. , Kleinerman, Judith, Kukreti, Vishal , Ma, Alice , Mueller, Brigitta U., O’Brien, Sarah H. , Pasquini, Marcelo C. , Haynes, Adam E., Hicks, Lisa K. , Sarode, Ravi , Solberg, Lawrence A. , Crowther, Mark Andrew

Hematology | December 6, 2013 | Volume: 2013 | Issue: 1 | Pages: 9-14

10.1182/asheducation-2013.1.9 | PMID 24319155 Get It

Abstract Choosing Wisely® is a medical stewardship and quality improvement initiative led by the American Board of Internal Medicine Foundation in collaboration with leading medical societies in the United States. The ASH is an active participant in the Choosing Wisely® project. Using an iterative process and an evidence-based method, ASH has identified 5 tests and treatments that in some circumstances are not well supported by evidence and which in certain cases involve a risk of adverse events and financial costs with low likelihood of benefit. The ASH Choosing Wisely® recommendations focus on avoiding liberal RBC transfusion, avoiding thrombophilia testing in adults in the setting of transient major thrombosis risk factors, avoiding inferior vena cava filter usage except in specified circumstances, avoiding the use of plasma or prothrombin complex concentrate in the nonemergent reversal of vitamin K antagonists, and limiting routine computed tomography surveillance after curative-intent treatment of non-Hodgkin lymphoma. We recommend that clinicians carefully consider anticipated benefits of the identified tests and treatments before performing them.